Evaluation of antiviral effects of the combination therapy of daclatasvir and asunaprevir

Evaluation of antiviral effects of the combination therapy of daclatasvir and asunaprevir - GLSG DCV/ASV

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000016995

Enrollment

100

Registered

2019-10-01

Start date

2014-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis C with genotype 1

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic hepatitis C with genotype 1

Exclusion criteria

Exclusion criteria: 1. Patients having the history of allergy to Daclatasvir and Asunaprevir 2. Women with pregnancy, having a possibility of pregnancy and during lactation 3. Patients taking a medicine described as a contraindication in a package insert. However, these patients can participate the study one month after discontinuation of the drug. 4. Patients whom the primary doctor thinks inapproprioate for participating the study.

Design outcomes

Primary

Measure	Time frame
antiviral effect (SVR24)	—

Countries

Japan

Contacts

Public ContactKen Sato

Gunma University Graduate School of Medicine Department of Medicine and Molecular Science

satoken@gunma-u.ac.jp027-220-8127

Outcome results